SCHEMBL903067

SCHEMBL903067

COc1ccccc1-c1onc(C)c1C(=O)O

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 10/20 0.48
HSD17B10 Q99714 7/20 0.48
HPGD P15428 7/20 0.48
KDM4E B2RXH2 5/20 0.48
TDP1 Q9NUW8 1/20 0.48
CA12 O43570 1/20 0.47
CA1 P00915 1/20 0.47
CA2 P00918 1/20 0.47
CA7 P43166 1/20 0.47
CA9 Q16790 1/20 0.47
CA14 Q9ULX7 1/20 0.47
RAB9A P51151 7/20 0.43
NPC1 O15118 5/20 0.43
SMN1; SMN2 Q16637 3/20 0.43
TP53 P04637 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
MEN1 O00255 4/20 0.43
KMT2A Q03164 4/20 0.43
NPSR1 Q6W5P4 2/20 0.43
MAPT P10636 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29058928 0.84 EPAS1 (0.43) ALDH1A1RAB9AL3MBTL1MEN1KMT2A
SCHEMBL12691873 0.82 NR1H4 (0.47) ALDH1A1HPGDKDM4ERAB9ASMN1; SMN2
SCHEMBL343837 0.81 EDNRB (0.43) ALDH1A1KDM4ERAB9ANPC1SMN1; SMN2
SCHEMBL30395754 0.79 KMT2A (0.49) ALDH1A1HSD17B10HPGDNPC1L3MBTL1
SCHEMBL12543516 0.79 KMT2A (0.49) ALDH1A1HSD17B10HPGDNPC1L3MBTL1
SCHEMBL12694204 0.79 TP53 (0.46) ALDH1A1HSD17B10HPGDKDM4ERAB9A
SCHEMBL457431 0.77 GPBAR1 (0.62) ALDH1A1HSD17B10HPGDKDM4ETDP1
SCHEMBL30394156 0.77 GPBAR1 (0.62) ALDH1A1HSD17B10HPGDKDM4ETDP1
SCHEMBL928538 0.77 PTGS1 (0.54) ALDH1A1HSD17B10KDM4ESMN1; SMN2TP53
Hydrochloric Acid SCHEMBL19119250 0.75 PTGS1 (0.53) ALDH1A1HSD17B10KDM4ESMN1; SMN2TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120245176-A1 NOVEL PIPERAZINE ANALOGS WITH SUBSTITUTED HETEROARYL GROUPS AS BROAD-SPECTRUM INFLUENZA ANTIVIRALS BRISTOL-MYERS SQUIBB COMPANY 2012-09-27 US disclosed
US-20120245176-A1 NOVEL PIPERAZINE ANALOGS WITH SUBSTITUTED HETEROARYL GROUPS AS BROAD-SPECTRUM INFLUENZA ANTIVIRALS BRISTOL-MYERS SQUIBB COMPANY 2012-09-27 US disclosed
WO-2012044531-A1 NOVEL PIPERAZINE ANALOGS WITH SUBSTITUTED HETEROARYL GROUPS AS BROAD-SPECTRUM INFLUENZA ANTIVIRALS BRISTOL-MYERS SQUIBB COMPANY (US) 2012-04-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120245176-A1 NOVEL PIPERAZINE ANALOGS WITH SUBSTITUTED HETEROARYL GROUPS AS BROAD-SPECTRUM INFLUENZA ANTIVIRALS ZC3HAV1, ZC3HAV1L, BAZ2A ALDH1A1 2107/4885HSD17B10 2876/4885HPGD 1877/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.